Key facts
- It has raised $45.3M; the latest was Later Stage VC in May 2025.
- Notable investors include Tech Incubator Program for Startup, KB Investment, IMM Investment, Posco Investment, Bluepoint Partners — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for GeneMedicine
- ·The full record, as it builds
Funding rounds
No funding rounds for GeneMedicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GeneMedicine
Developer of oncology therapeutic medicines designed to treat intractable cancers. The company's medicines utilize novel and innovative adenoviral vector platforms, which can selectively lyse cancer cells, express numerous combinations of therapeutic transgenes, and deliver systemic treatments based on oncolytic adenovirus against solid tumors, pancreatic cancers, and metastatic lung and liver cancers, enabling healthcare professionals to get innovative treatment methods in the fields of oncolytic virotherapy and gene and cell therapy.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2014
- Employees
- 18
- Website
- gene-medicine.com/
- Ownership
- Privately Held (backing)
GeneMedicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GeneMedicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GeneMedicine in its N-PORT filings yet. We sweep new filings monthly.